Research programme: anti-cancer immunotherapies - University College London/Tusk Therapeutics/Cancer Research Technology

Drug Profile

Research programme: anti-cancer immunotherapies - University College London/Tusk Therapeutics/Cancer Research Technology

Latest Information Update: 14 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University College London
  • Developer Cancer Research Technology; Tusk Therapeutics; University College London
  • Class Antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 07 Feb 2017 Cancer Research Technology, University College London, and Tusk Therapeutics agree to research, develop and commercialise antibody-based immunotherapies in United Kingdom for cancer
  • 07 Feb 2017 Tusk Therapeutics agree to fund preclinical antibody therapeutics co-developed by University College London and Cancer Research Technology in United Kingdom for Cancer
  • 07 Feb 2017 Early research in Cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top